Your browser doesn't support javascript.
loading
The interaction of spongistatin 1 with tubulin.
Bai, Ruoli; Smith, Amos B; Pettit, George R; Hamel, Ernest.
Afiliación
  • Bai R; Molecular Pharmacology Branch (RB, EH), Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702, USA.
  • Smith AB; Department of Chemistry, University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Pettit GR; Laboratory for Discovery of Anti-Cancer and Anti-Infective Drugs, School of Molecular Sciences, Arizona State University, Tempe, AZ, 85287, USA.
  • Hamel E; Molecular Pharmacology Branch (RB, EH), Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702, USA. Electronic address: hamele@mail.nih.gov.
Arch Biochem Biophys ; 727: 109296, 2022 09 30.
Article en En | MEDLINE | ID: mdl-35594923
ABSTRACT
A tritiated derivative of the sponge-derived natural product spongistatin 1 was prepared, and its interactions with tubulin were examined. [3H]Spongistatin 1 was found to bind rapidly to tubulin at a single site (the low specific activity of the [3H]spongistatin 1, 0.75 Ci/mmol, prevented our defining an association rate), and the inability of spongistatin 1 to cause an aberrant assembly reaction was confirmed. Spongistatin 1 bound to tubulin very tightly, and we could detect no significant dissociation reaction from tubulin. The tubulin-[3H]spongistatin 1 complex did dissociate in 8 M urea, so there was no evidence for covalent bond formation. Apparent KD values were obtained by Scatchard analysis of binding data and by Hummel-Dreyer chromatography (3.5 and 1.1 µM, respectively). The effects of a large cohort of vinca domain drugs on the binding of [3H]spongistatin 1 to tubulin were evaluated. Compounds that did not cause aberrant assembly reactions (halichondrin B, eribulin, maytansine, and rhizoxin) caused little inhibition of [3H]spongistatin 1 binding. Little inhibition also occurred with the peptides dolastatin 15, its active pentapeptide derivative, vitilevuamide, or diazonamide A, nor with the vinca alkaloid vinblastine. Strong inhibition was observed with dolastatin 10, hemiasterlin, and cryptophycin 1, all of which cause aberrant assembly reactions that might actually mask the spongistatin 1 binding site. Spongistatin 5 was found to be a competitive inhibitor of [3H]spongistatin 1 binding, with an apparent Ki of 2.2 µM. We propose that the strong picomolar cytotoxicity of spongistatin 1 probably derives from its extremely tight binding to tubulin.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tubulina (Proteína) / Antineoplásicos Tipo de estudio: Clinical_trials Idioma: En Revista: Arch Biochem Biophys Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tubulina (Proteína) / Antineoplásicos Tipo de estudio: Clinical_trials Idioma: En Revista: Arch Biochem Biophys Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos